drugset / Trial / NCT01983306
Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of a range of oral SP-333 doses for the treatment of opioid-induced constipation (OIC) in adults with non-cancer pain taking opioids.
Timeline
- Start
- 2013-11
- Primary completion
- 2014-09
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dolcanatide | Protein / enzyme biologic | 1 mg | Oral |
| Subject | Dolcanatide | Protein / enzyme biologic | 3 mg | Oral |
| Subject | Dolcanatide | Protein / enzyme biologic | 6 mg | Oral |